A Pioneering Platform for Precision Therapies

Hummingbird Bioscience’s Rational Antibody Discovery platform leverages data-rich, systems biology approaches to identify critical functional regions of a target protein, drive production of antibodies against these epitopes, and then isolate the antibodies that bind to them, thereby optimizing the therapeutic potential of a target.

This systematic and rational approach overcomes many of the common challenges such as tolerance and epitope instability, and allows us to efficiently and precisely engineer next-generation precision therapies that uniquely hit the right targets for the right patients.

Rational Antibody Discovery Platform


uses an immunoengineering system to manipulate an immune response to control the production of antibodies against defined optimal yet elusive epitopes on a disease associated protein. mAbHits increases the proportion of usable therapeutic antibodies.


uses AI-powered computational biology to integrate and analyze data from multidisciplinary sources to produce validated insights into the biology of the disease and provide predictions regarding which epitopes on a disease associated protein will yield antibodies with optimal efficacy and safety profiles.

Classical Approaches vs. Rational Antibody Discovery

Missing the Mark

Classical approaches to antibody discovery often led to the majority of antibodies produced missing the optimal epitopes.

Hitting the Spot

Our Rational Antibody Discovery platform systematically identifies optimal target epitopes, and immunoengineers an immune response that results in majority of the resulting antibodies hitting the desired epitopes.

Applications of our Platform